BioCentury | Jun 19, 2019
Distillery Therapeutics

Agonizing TrkB to restore cognitive function after chemotherapy

...Neurotrophic tyrosine kinase receptor 2 (TrkB; NTRK2) EXPERIMENTAL SYSTEM: Mice LICENSING STATUS: Patented; licensed to PharmatrophiX Inc....
...published online May 20, 2019 doi:10.1016/j.neuron.2019.04.032 CONTACT: Michelle Monje, Stanford University, Stanford, Calif. e-mail: mmonje@stanford.edu Sandi Wong PharmatrophiX Inc. Stanford...
BioCentury | May 6, 2010
Distillery Therapeutics

Indication: Neurology

...The University of North Carolina and the University of California, San Francisco; exclusively licensed to PharmatrophiX Inc....
BioCentury | May 6, 2010
Targets & Mechanisms

New Trk for an old protein

...<0.01). The findings were published in The Journal of Clinical Investigation . Longo also cofounded PharmatrophiX Inc....
...University of North Carolina at Chapel Hill (UNC), before joining the Stanford faculty in 2005. PharmatrophiX...
...and tissue culture, the compounds blocked neuronal death caused by AD-associated b-amyloid. 9,10 Last year, PharmatrophiX...
BioCentury | Jul 13, 2009
Company News

Elan, PharmatrophiX deal

...in 2011 or 2012. Financial terms were not disclosed. Elan Corp. plc (NYSE:ELN), Dublin, Ireland PharmatrophiX Inc....
BioCentury | Jul 6, 2009
Strategy

Bailing out Elan

...colitis (UC) and Crohn's. Kelly also plans to step up in-licensing. "Our recent partnership with PharmatrophiX...
...we move forward in the coming months." Last month, Elan received a global license from PharmatrophiX...
...Indianapolis, Ind. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. PharmatrophiX...
Items per page:
1 - 5 of 5
BioCentury | Jun 19, 2019
Distillery Therapeutics

Agonizing TrkB to restore cognitive function after chemotherapy

...Neurotrophic tyrosine kinase receptor 2 (TrkB; NTRK2) EXPERIMENTAL SYSTEM: Mice LICENSING STATUS: Patented; licensed to PharmatrophiX Inc....
...published online May 20, 2019 doi:10.1016/j.neuron.2019.04.032 CONTACT: Michelle Monje, Stanford University, Stanford, Calif. e-mail: mmonje@stanford.edu Sandi Wong PharmatrophiX Inc. Stanford...
BioCentury | May 6, 2010
Distillery Therapeutics

Indication: Neurology

...The University of North Carolina and the University of California, San Francisco; exclusively licensed to PharmatrophiX Inc....
BioCentury | May 6, 2010
Targets & Mechanisms

New Trk for an old protein

...<0.01). The findings were published in The Journal of Clinical Investigation . Longo also cofounded PharmatrophiX Inc....
...University of North Carolina at Chapel Hill (UNC), before joining the Stanford faculty in 2005. PharmatrophiX...
...and tissue culture, the compounds blocked neuronal death caused by AD-associated b-amyloid. 9,10 Last year, PharmatrophiX...
BioCentury | Jul 13, 2009
Company News

Elan, PharmatrophiX deal

...in 2011 or 2012. Financial terms were not disclosed. Elan Corp. plc (NYSE:ELN), Dublin, Ireland PharmatrophiX Inc....
BioCentury | Jul 6, 2009
Strategy

Bailing out Elan

...colitis (UC) and Crohn's. Kelly also plans to step up in-licensing. "Our recent partnership with PharmatrophiX...
...we move forward in the coming months." Last month, Elan received a global license from PharmatrophiX...
...Indianapolis, Ind. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. PharmatrophiX...
Items per page:
1 - 5 of 5